Amarin (NASDAQ:AMRN) Upgraded at StockNews.com

StockNews.com upgraded shares of Amarin (NASDAQ:AMRN) from a sell rating to a hold rating in a research note released on Friday.

Amarin Trading Down 0.8 %

Shares of Amarin stock opened at $0.53 on Friday. Amarin has a 12-month low of $0.43 and a 12-month high of $1.11. The stock has a market cap of $217.66 million, a PE ratio of -5.89 and a beta of 1.82. The company has a 50-day moving average of $0.56 and a two-hundred day moving average of $0.56.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in AMRN. Kornitzer Capital Management Inc. KS increased its holdings in Amarin by 80.7% in the third quarter. Kornitzer Capital Management Inc. KS now owns 95,600 shares of the biopharmaceutical company’s stock valued at $60,000 after buying an additional 42,700 shares in the last quarter. BNP Paribas Financial Markets increased its holdings in Amarin by 8.8% in the third quarter. BNP Paribas Financial Markets now owns 1,301,468 shares of the biopharmaceutical company’s stock valued at $816,000 after buying an additional 104,939 shares in the last quarter. Arkfeld Wealth Strategies L.L.C. increased its holdings in Amarin by 52.6% in the fourth quarter. Arkfeld Wealth Strategies L.L.C. now owns 58,000 shares of the biopharmaceutical company’s stock valued at $30,000 after buying an additional 20,000 shares in the last quarter. LCM Capital Management Inc increased its holdings in Amarin by 3.1% in the fourth quarter. LCM Capital Management Inc now owns 838,259 shares of the biopharmaceutical company’s stock valued at $407,000 after buying an additional 25,100 shares in the last quarter. Finally, New York State Common Retirement Fund acquired a new stake in shares of Amarin in the fourth quarter valued at approximately $68,000. 22.25% of the stock is owned by hedge funds and other institutional investors.

Amarin Company Profile

Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.